Exosomes are small extracellular vesicles that cells release to carry proteins, lipids and RNA to other cells. As biology this is real and genuinely interesting. As a product sold in clinics for hair loss, skin rejuvenation, joints and a long list of other things, it is something else: an area where the marketing has run far ahead of both the evidence and the law. The single most important fact about exosome therapy is regulatory, so it goes first.
The regulatory position, stated plainly
A clinic offering you an exosome injection is therefore not offering an approved therapy, whatever the consent form says. That is a statement about legal and regulatory status, which is checkable, not a prediction about whether the biology will eventually work out.
The research that does exist
It would be wrong to suggest nothing serious is happening. A first-in-human clinical trial tested allogeneic platelet-derived extracellular vesicles as a potential therapeutic for delayed wound healing — a properly conducted early-phase study published in a specialist extracellular-vesicle journal.[1] More usefully for judging the field as a whole, a 2024 systematic review and meta-analysis assessed the safety and efficacy of human extracellular-vesicle-based therapy across the clinical trials conducted to date.[2] A separate 2024 critical review surveyed clinical applications of exosomes and their limitations.[4]
This is what a legitimate early-stage field looks like: first-in-human safety work, systematic attempts to pool what little exists, and reviews that are candid about how preliminary it all is. None of it establishes efficacy for the indications being sold commercially.
Hair loss, the most marketed use
Exosomes for hair regeneration are promoted heavily, often alongside peptide-based approaches. The dermatology literature has looked at this directly: a 2025 review in Dermatologic Surgery examined the clinical studies of exosomes for treating hair loss.[3] The picture it describes is a small and preliminary evidence base — which is a considerable distance from the confidence of the marketing, and worth knowing before paying for a course of injections priced in the thousands.
“Exosome” does not tell you what is in the vial
Even setting regulation aside, the word is close to uninformative as a product description. What was the source cell — umbilical cord, placenta, adipose, platelet? How were the vesicles isolated, and how were they characterized afterwards? What dose, by what measure? Preparations that share the label “exosome” can differ more from one another than two entirely different drugs do. When a clinic cannot answer those questions from documentation, the honest reading is that nobody knows what is being administered.
Where this leaves a reader
Exosome biology is a legitimate and active research field that may well produce approved therapies. It has not produced one yet. Between those two facts sits a large commercial market selling unapproved preparations for conditions no trial has shown they treat, at prices that assume the opposite. If you want to follow the science, follow the trial registrations and the early-phase literature. If someone is asking you to pay for an injection today, the relevant question is not whether exosomes are promising — it is whether there is an IND, and there almost certainly is not.
For an adjacent area where the regulatory status is similarly decisive, see our coverage of NAD⁺ IV therapy.
This is a research summary, not medical advice, and nothing here should be read as a recommendation to seek exosome treatment. No exosome product is approved by the FDA for any indication. Adverse events associated with unapproved regenerative-medicine products can be reported to the FDA’s MedWatch program. Talk to a qualified clinician about any treatment decision.